HRP20230742T1 - Lrrc33 inhibitori i njihova uporaba - Google Patents
Lrrc33 inhibitori i njihova uporaba Download PDFInfo
- Publication number
- HRP20230742T1 HRP20230742T1 HRP20230742TT HRP20230742T HRP20230742T1 HR P20230742 T1 HRP20230742 T1 HR P20230742T1 HR P20230742T T HRP20230742T T HR P20230742TT HR P20230742 T HRP20230742 T HR P20230742T HR P20230742 T1 HRP20230742 T1 HR P20230742T1
- Authority
- HR
- Croatia
- Prior art keywords
- lrrc33
- inhibitor
- use according
- individual
- fibrosis
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims 27
- 101150079786 NRROS gene Proteins 0.000 title 1
- 101001004913 Homo sapiens Transforming growth factor beta activator LRRC33 Proteins 0.000 claims 36
- 102100025954 Transforming growth factor beta activator LRRC33 Human genes 0.000 claims 34
- 210000004027 cell Anatomy 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 206010016654 Fibrosis Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 230000004761 fibrosis Effects 0.000 claims 5
- 208000032839 leukemia Diseases 0.000 claims 5
- 210000002540 macrophage Anatomy 0.000 claims 4
- 238000011275 oncology therapy Methods 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 3
- 230000002489 hematologic effect Effects 0.000 claims 3
- 230000001506 immunosuppresive effect Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 238000001565 modulated differential scanning calorimetry Methods 0.000 claims 3
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 231100000419 toxicity Toxicity 0.000 claims 3
- 230000001988 toxicity Effects 0.000 claims 3
- 210000004981 tumor-associated macrophage Anatomy 0.000 claims 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 230000007236 host immunity Effects 0.000 claims 2
- 102000048304 human NRROS Human genes 0.000 claims 2
- 206010028537 myelofibrosis Diseases 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 206010019851 Hepatotoxicity Diseases 0.000 claims 1
- 101000771075 Homo sapiens Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101001004924 Homo sapiens Transforming growth factor beta activator LRRC32 Proteins 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 206010051792 Infusion related reaction Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010050207 Skin fibrosis Diseases 0.000 claims 1
- 206010067269 Uterine fibrosis Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000003651 basophil Anatomy 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 230000000779 depleting effect Effects 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000007686 hepatotoxicity Effects 0.000 claims 1
- 231100000304 hepatotoxicity Toxicity 0.000 claims 1
- 102000052917 human LRRC32 Human genes 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 210000003593 megakaryocyte Anatomy 0.000 claims 1
- 210000000135 megakaryocyte-erythroid progenitor cell Anatomy 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 210000004980 monocyte derived macrophage Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 208000003476 primary myelofibrosis Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Claims (17)
1. LRRC33 inhibitor, naznačen time, da je za uporabu u:
(a) liječenju hematološkog proliferativnog poremećaja, solidnog tumora, i/ili fibroze kod pojedinca; i/ili
(b) postupku liječenja pojedinca putem deplecije stanica koje eksprimiraju LRRC33 na staničnu površinu kod pojedinca, pri čemu postupak obuhvaća korak davanja LRRC33 inhibitora pojedincu u količini koja je učinkovita tako da smanjuje broj stanica koje eksprimiraju LRRCF33 na staničnu površinu, dok pojedinac boluje od bolesti koja je povezana s prekomjernom ekspresijom LRRC33 i/ili abnormalnom aktivacijom makrofaga, pri čemu je bolest fibroza, miopatija ili tumor; i/ili
(c) terapijskom postupku, gdje postupak obuhvaća preokretanje imunosupresivnog okruženja bolesti, tako da se snažno pojača imunitet kod pojedinca,
pri čemu inhibitor je protutijelo ili njegov fragment koji specifično veže epitop prisutan na izvanstaničnom odsječku od LRRC33 ili od kompleksa koji sadrži LRRC33, koji se nalazi na staničnoj površini,
i pri čemu protutijelo inducira internalizaciju LRRC33 ili kompleksa koji sadrži LRRC33 na staničnoj površini.
2. LRRC33 inhibitor za uporabu prema patentnom zahtjevu 1, naznačen time, da LRRC33 inhibitor nadalje obuhvaća citotoksično sredstvo.
3. LRRC33 inhibitor za uporabu prema patentnom zahtjevu 1 ili 2, naznačen time, da pojedinac ima hematološki proliferativni poremećaj odabran od leukemije, limfoma, mijelofibroze i multiplog mijeloma.
4. LRRC33 inhibitor za uporabu prema patentnom zahtjevu 3, naznačen time, da hematološki proliferativni poremećaj je leukemija, pri čemu opcionalno leukemija je akutna mijeloična leukemija (AML), akutna limfoblastna leukemija (ALL), kronična leukemija limfocita (CLL) ili kronična mijeloična leukemija (CML).
5. LRRC33 inhibitor za uporabu prema patentnom zahtjevu 1 ili 2, naznačen time, da je LRRC33 inhibitor za uporabu u liječenju solidnog tumora, opcionalno gdje je solidni tumor obogaćen s makrofagima povezanima s tumorom (TAMs).
6. LRRC33 inhibitor za uporabu prema patentnom zahtjevu 5, naznačen time, da je solidni tumor obogaćen s makrofagima M2c i/ili makrofagima nalik na TAM (M2d).
7. LRRC33 inhibitor za uporabu prema patentnom zahtjevu 1 ili 2, naznačen time, da je LRRC33 inhibitor za uporabu u liječenju fibroze, pri čemu fibroza obuhvaća fibrozno tkivo obogaćeno s makrofagima koji su izvedeni iz monocita, gdje opcionalno fibroza je plućna fibroza, fibroza bubrega, fibroza jetre, fibroza srca, fibroza koštane srži, fibroza maternice i/ili kožna fibroza.
8. LRRC33 inhibitor za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da LRRC33 inhibitor vrši depleciju stanica koje eksprimiraju LRRC33 na staničnu površinu, pri čemu su stanice koje eksprimiraju LRRC33 na staničnu površinu sljedeće: TAMs, TANs, MDSCs, CAFs, leukemijske stanice, hematopoietske matične stanice, mijeloične progenitorne stanice, limfoidne progenitorne stanice, megakariocit-eritroidne progenitorne stanice, megakariociti, monociti, B stanice, NK stanice, neutrofili, eozinofili, bazofili, i/ili makrofagi.
9. LRRC33 inhibitor za uporabu prema patentnom zahtjevu 8, naznačen time, da stanice koje eksprimiraju LRRC33 na staničnu površinu su MDSCs, i time, da su MDSCs prisutni u mikrookolišu tumora.
10. LRRC33 inhibitor za uporabu prema patentnom zahtjevu 1 ili 2, naznačen time, da liječenje preokreće imunosupresivni okoliš bolesti kod pojedinca, pri čemu opcionalno okoliš bolesti je TME ili fibrozno tkivo.
11. LRRC33 inhibitor za uporabu prema bilo kojem od patentnih zahtjeva 1-4, ili 8, naznačen time, da je inhibitor za uporabu u postupku liječenja leukemije kod pojedinca, pri čemu davanje LRRC33 inhibitora u učinkovitoj dozi uzrokuje manje toksičnosti u usporedbi sa CD33 terapijom, dok opcionalno toksičnost uključuje: hepatotoksičnost, reakcije povezane s infuzijom, hemoragiju, prolongaciju QT intervala, infekciju, anemiju, embrio-fetalnu toksičnost, i/ili smrt.
12. LRRC33 inhibitor za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da LRRC33 inhibitor pojačava imunitet domaćina protiv raka kod pojedinca, pri čemu se pojedinac liječi terapijom za rak, gdje opcionalno, terapija za rak je CAR-T terapija, terapija inhibitorom kontrolne točke, kemoterapija, ili terapija zračenjem.
13. LRRC33 inhibitor za uporabu prema patentnom zahtjevu 12, naznačen time, da se imunitet domaćina pojačava putem smanjivanja imunosupresije.
14. LRRC33 inhibitor za uporabu prema patentnom zahtjevu 12 ili 13, naznačen time, da uporaba LRRC33 inhibitora čini da rak bude osjetljiviji na terapiju za rak.
15. LRRC33 inhibitor za uporabu prema bilo kojem od patentnih zahtjeva 12-14, naznačen time, da pojedinac prima smanjenu količinu terapije za rak u usporedbi s monoterapijom, kako bi se postigla ista ili ekvivalentna terapijska korist/efikasnost.
16. LRRC33 inhibitor za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da je LRRC33 povezan s latentnim TGFβ kompleksom, pri čemu opcionalno latentni TGFβ kompleks jest latentni TGFβ1 kompleks.
17. Farmaceutski pripravak, naznačen time, da sadrži protutijelo koje veže ljudski LRRC33 ili kompleks koji sadrži ljudski LRRC33 na staničnoj površini, pri čemu protutijelo sadrži citotoksično sredstvo, i pri čemu protutijelo ne veže ljudski GARP.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762503785P | 2017-05-09 | 2017-05-09 | |
| US201762558048P | 2017-09-13 | 2017-09-13 | |
| US201862663030P | 2018-04-26 | 2018-04-26 | |
| US201862666182P | 2018-05-03 | 2018-05-03 | |
| PCT/US2018/031759 WO2018208888A1 (en) | 2017-05-09 | 2018-05-09 | Lrrc33 inhibitors and use thereof |
| EP18727561.5A EP3621694B1 (en) | 2017-05-09 | 2018-05-09 | Lrrc33 inhibitors and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230742T1 true HRP20230742T1 (hr) | 2023-10-27 |
Family
ID=62245483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230742TT HRP20230742T1 (hr) | 2017-05-09 | 2018-05-09 | Lrrc33 inhibitori i njihova uporaba |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20200181251A1 (hr) |
| EP (2) | EP4286013A3 (hr) |
| JP (1) | JP2020519579A (hr) |
| AU (1) | AU2018266784A1 (hr) |
| CA (1) | CA3099260A1 (hr) |
| DK (1) | DK3621694T3 (hr) |
| ES (1) | ES2958587T3 (hr) |
| FI (1) | FI3621694T3 (hr) |
| HR (1) | HRP20230742T1 (hr) |
| HU (1) | HUE063120T2 (hr) |
| LT (1) | LT3621694T (hr) |
| PL (1) | PL3621694T3 (hr) |
| PT (1) | PT3621694T (hr) |
| SI (1) | SI3621694T1 (hr) |
| WO (1) | WO2018208888A1 (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018316166A1 (en) | 2017-08-07 | 2020-02-06 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
| US11230601B2 (en) | 2017-10-10 | 2022-01-25 | Tilos Therapeutics, Inc. | Methods of using anti-lap antibodies |
| JP2022504839A (ja) | 2018-10-10 | 2022-01-13 | ティロス・セラピューティクス・インコーポレイテッド | 抗ｌａｐ抗体変異体及びその使用 |
| WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| WO2022256723A2 (en) | 2021-06-03 | 2022-12-08 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
| CN114807038B (zh) * | 2022-02-11 | 2023-11-10 | 四川大学华西第二医院 | 一种小鼠淋巴瘤相关成纤维细胞肿瘤细胞HXLyAF-KT及其应用 |
| WO2024018046A1 (en) | 2022-07-22 | 2024-01-25 | Institut National de la Santé et de la Recherche Médicale | Garp as a biomarker and biotarget in t-cell malignancies |
| WO2024023283A1 (en) | 2022-07-29 | 2024-02-01 | Institut National de la Santé et de la Recherche Médicale | Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3023553A1 (en) | 2012-11-06 | 2014-05-15 | Scholar Rock, Inc. | Compositions and methods for modulating cell signaling |
| RS61778B1 (sr) | 2013-05-06 | 2021-06-30 | Scholar Rock Inc | Kompozicije i postupci za modulaciju faktora rasta |
| KR20180122397A (ko) | 2016-03-11 | 2018-11-12 | 스칼러 락, 인크. | TGFβ1-결합 이뮤노글로불린 및 그의 용도 |
| EP3532494A4 (en) | 2016-10-26 | 2020-06-03 | The Children's Medical Center Corporation | METHOD AND COMPOSITIONS FOR MODULATING TRANSFORMATION GROWTH FACTOR BETA-REGULATED FUNCTIONS |
-
2018
- 2018-05-09 JP JP2019560657A patent/JP2020519579A/ja active Pending
- 2018-05-09 HR HRP20230742TT patent/HRP20230742T1/hr unknown
- 2018-05-09 PT PT187275615T patent/PT3621694T/pt unknown
- 2018-05-09 WO PCT/US2018/031759 patent/WO2018208888A1/en unknown
- 2018-05-09 AU AU2018266784A patent/AU2018266784A1/en active Pending
- 2018-05-09 ES ES18727561T patent/ES2958587T3/es active Active
- 2018-05-09 SI SI201830969T patent/SI3621694T1/sl unknown
- 2018-05-09 HU HUE18727561A patent/HUE063120T2/hu unknown
- 2018-05-09 CA CA3099260A patent/CA3099260A1/en active Pending
- 2018-05-09 PL PL18727561.5T patent/PL3621694T3/pl unknown
- 2018-05-09 EP EP23183427.6A patent/EP4286013A3/en active Pending
- 2018-05-09 US US16/611,029 patent/US20200181251A1/en not_active Abandoned
- 2018-05-09 EP EP18727561.5A patent/EP3621694B1/en active Active
- 2018-05-09 LT LTEPPCT/US2018/031759T patent/LT3621694T/lt unknown
- 2018-05-09 FI FIEP18727561.5T patent/FI3621694T3/fi active
- 2018-05-09 DK DK18727561.5T patent/DK3621694T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| LT3621694T (lt) | 2023-11-27 |
| ES2958587T3 (es) | 2024-02-12 |
| DK3621694T3 (da) | 2023-09-11 |
| US20200181251A1 (en) | 2020-06-11 |
| PL3621694T3 (pl) | 2024-02-05 |
| HUE063120T2 (hu) | 2023-12-28 |
| AU2018266784A1 (en) | 2019-12-05 |
| EP3621694A1 (en) | 2020-03-18 |
| EP4286013A3 (en) | 2024-02-28 |
| SI3621694T1 (sl) | 2023-10-30 |
| FI3621694T3 (fi) | 2023-08-28 |
| JP2020519579A (ja) | 2020-07-02 |
| EP3621694B1 (en) | 2023-07-05 |
| CA3099260A1 (en) | 2018-11-15 |
| EP4286013A2 (en) | 2023-12-06 |
| PT3621694T (pt) | 2023-10-09 |
| WO2018208888A1 (en) | 2018-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230742T1 (hr) | Lrrc33 inhibitori i njihova uporaba | |
| Miller et al. | HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer | |
| Chen et al. | Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin lymphoma | |
| Vaisitti et al. | ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models | |
| Gingis-Velitski et al. | Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice | |
| US20180179282A1 (en) | Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways | |
| Yang et al. | Nrf2 inhibitor, brusatol in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive cancers by inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 pathways | |
| RU2670127C2 (ru) | Композиции, включающие антитела к cd38 и карфилзомиб | |
| US11230598B2 (en) | Antibodies and methods for depleting regulatory bio cells and use in combination with immune checkpoint inhibitors | |
| TW202313113A (zh) | 藉由投予pd-1抑制劑治療皮膚癌之方法 | |
| Li et al. | Combined yeast β-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55 | |
| Qu et al. | Nimotuzumab enhances the radiosensitivity of cancer cells in vitro by inhibiting radiation-induced DNA damage repair | |
| KR20180011315A (ko) | 항-cd37 면역접합체 및 항-cd20 항체 조합 | |
| JP2017506227A5 (hr) | ||
| Dienstmann et al. | Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development | |
| Gopal et al. | Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients | |
| Watkins et al. | CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas | |
| Goldberg et al. | Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: a phase I study | |
| Nytko et al. | The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy | |
| Dinner et al. | Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia | |
| JP2021525735A (ja) | 抗ｃｄ３７免疫コンジュゲート投薬レジメン | |
| Assis et al. | Halofuginone inhibits phosphorylation of SMAD-2 reducing angiogenesis and leukemia burden in an acute promyelocytic leukemia mouse model | |
| Hu et al. | The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia | |
| Blattmann et al. | Radiosensitization by histone deacetylase inhibition in an osteosarcoma mouse model | |
| Donato et al. | Monoclonal antibodies currently in Phase II and III trials for multiple myeloma |